Literature DB >> 21970857

Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma.

Jianbo Wang1, Kaihua Zhang, Dorota Grabowska, Aimin Li, Yiyu Dong, Ryan Day, Peter Humphrey, James Lewis, Raleigh D Kladney, Jeffrey M Arbeit, Jason D Weber, Christine H Chung, Loren S Michel.   

Abstract

Trop2, an oncogenic cell surface protein under investigation as a therapeutic target, is commonly overexpressed in several epithelial tumor types yet its function in tumor biology remains relatively unexplored. To investigate the role of Trop2 in epithelial carcinogenesis, we generated Trop2(-/-) mice, which are viable and possess a normal lifespan. Contrary to expectations, Trop2 loss fails to suppress keratinocyte transformation. Instead, ras-transformed Trop2(-/-) keratinocytes preferentially pass through an epithelial to mesenchymal transition (EMT) and form tumors with spindle cell histology. Furthermore, Trop2 loss renders Arf-null mice susceptible to the formation of biphasic sarcomatoid carcinomas containing both squamous and spindle cell components upon carcinogen exposure in an otherwise skin cancer-resistant strain (C57BL/6). Immortalized keratinocytes derived from Trop2(-/-)Arf(-/-) mice exhibit enhanced proliferative and migratory capacity as well as increased activation of mitogen-activated protein kinase and Src prior to transformation. The clinical relevance of these findings was supported by studying the molecular epidemiology of Trop2 in primary head and neck squamous cell carcinomas. This analysis revealed that Trop2 mRNA levels are decreased in a subset of tumors with features of EMT, and total loss of Trop2 protein expression is observed in the spindle cell component of sarcomatoid carcinomas. Therefore, while previous studies have emphasized the potential importance of Trop2 gain of function, these results uncover a role for Trop2 loss in tumorigenesis and the mesenchymal transdifferentiation observed in a subset of squamous cell carcinomas.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21970857      PMCID: PMC3243826          DOI: 10.1158/1541-7786.MCR-11-0241

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  47 in total

1.  Nuclear signalling by tumour-associated antigen EpCAM.

Authors:  Dorothea Maetzel; Sabine Denzel; Brigitte Mack; Martin Canis; Philip Went; Michael Benk; Cuong Kieu; Peer Papior; Patrick A Baeuerle; Markus Munz; Olivier Gires
Journal:  Nat Cell Biol       Date:  2009-01-11       Impact factor: 28.824

2.  Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways.

Authors:  Tamer T Onder; Piyush B Gupta; Sendurai A Mani; Jing Yang; Eric S Lander; Robert A Weinberg
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

3.  Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody.

Authors:  Joyce Varughese; Emiliano Cocco; Stefania Bellone; Maria de Leon; Marta Bellone; Paola Todeschini; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin
Journal:  Cancer       Date:  2011-01-18       Impact factor: 6.860

4.  Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications.

Authors:  Erika L Abel; Joe M Angel; Kaoru Kiguchi; John DiGiovanni
Journal:  Nat Protoc       Date:  2009-08-27       Impact factor: 13.491

5.  Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics.

Authors:  Andrew S Goldstein; Devon A Lawson; Donghui Cheng; Wenyi Sun; Isla P Garraway; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-16       Impact factor: 11.205

6.  Potential hepatic stem cells reside in EpCAM+ cells of normal and injured mouse liver.

Authors:  Mayuko Okabe; Yuko Tsukahara; Minoru Tanaka; Kaori Suzuki; Shigeru Saito; Yoshiko Kamiya; Tohru Tsujimura; Koji Nakamura; Atsushi Miyajima
Journal:  Development       Date:  2009-06       Impact factor: 6.868

Review 7.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

Review 8.  Trop2: a possible therapeutic target for late stage epithelial carcinomas.

Authors:  Rafael Cubas; Min Li; Changyi Chen; Qizhi Yao
Journal:  Biochim Biophys Acta       Date:  2009-08-14

9.  A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model.

Authors:  Bryan Serrels; Alan Serrels; Susan M Mason; Christine Baldeschi; Gabrielle H Ashton; M Canel; Lorna J Mackintosh; Brendan Doyle; Tim P Green; Margaret C Frame; Owen J Sansom; Valerie G Brunton
Journal:  Carcinogenesis       Date:  2008-12-05       Impact factor: 4.944

10.  TROP2 expression as prognostic marker for gastric carcinoma.

Authors:  G Mühlmann; G Spizzo; J Gostner; M Zitt; H Maier; P Moser; G Gastl; M Zitt; H M Müller; R Margreiter; D Ofner; D Fong
Journal:  J Clin Pathol       Date:  2008-10-17       Impact factor: 3.411

View more
  26 in total

1.  Trophoblast cell surface antigen 2 (Trop-2) phosphorylation by protein kinase C α/δ (PKCα/δ) enhances cell motility.

Authors:  Yugo Mori; Kaoru Akita; Kazuki Ojima; Shungo Iwamoto; Tomoko Yamashita; Eiichi Morii; Hiroshi Nakada
Journal:  J Biol Chem       Date:  2019-06-07       Impact factor: 5.157

2.  Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling.

Authors:  Tanya Stoyanova; Andrew S Goldstein; Houjian Cai; Justin M Drake; Jiaoti Huang; Owen N Witte
Journal:  Genes Dev       Date:  2012-10-15       Impact factor: 11.361

3.  The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.

Authors:  Michelle Shen; Shiqin Liu; Tanya Stoyanova
Journal:  Am J Clin Exp Urol       Date:  2021-02-15

4.  Trop-2 in Upper Tract Urothelial Carcinoma.

Authors:  Eisuke Tomiyama; Kazutoshi Fujita; Kosuke Nakano; Ken Kuwahara; Takafumi Minami; Taigo Kato; Koji Hatano; Atsunari Kawashima; Motohide Uemura; Tetsuya Takao; Hiroaki Fushimi; Kotoe Katayama; Seiya Imoto; Kazuhiro Yoshimura; Ryoichi Imamura; Hirotsugu Uemura; Norio Nonomura
Journal:  Curr Oncol       Date:  2022-05-30       Impact factor: 3.109

5.  EPCAM and TROP2 share a role in claudin stabilization and development of intestinal and extraintestinal epithelia in mice.

Authors:  Roman Szabo; Jerrold M Ward; Ferruh Artunc; Thomas H Bugge
Journal:  Biol Open       Date:  2022-07-11       Impact factor: 2.643

6.  Trop-2 promotes prostate cancer metastasis by modulating β(1) integrin functions.

Authors:  Marco Trerotola; Danielle L Jernigan; Qin Liu; Javed Siddiqui; Alessandro Fatatis; Lucia R Languino
Journal:  Cancer Res       Date:  2013-03-27       Impact factor: 12.701

7.  TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma.

Authors:  Jau-Chen Lin; Yi-Ying Wu; Jing-Yi Wu; Tzu-Chieh Lin; Chen-Tu Wu; Yih-Leong Chang; Yuh-Shan Jou; Tse-Ming Hong; Pan-Chyr Yang
Journal:  EMBO Mol Med       Date:  2012-03-15       Impact factor: 12.137

Review 8.  Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications.

Authors:  Anna Shvartsur; Benjamin Bonavida
Journal:  Genes Cancer       Date:  2015-03

9.  Loss of TACSTD2 contributed to squamous cell carcinoma progression through attenuating TAp63-dependent apoptosis.

Authors:  F Wang; X Liu; P Yang; L Guo; C Liu; H Li; S Long; Y Shen; H Wan
Journal:  Cell Death Dis       Date:  2014-03-20       Impact factor: 8.469

10.  A surprising cross-species conservation in the genomic landscape of mouse and human oral cancer identifies a transcriptional signature predicting metastatic disease.

Authors:  Michael D Onken; Ashley E Winkler; Krishna-Latha Kanchi; Varun Chalivendra; Jonathan H Law; Charles G Rickert; Dorina Kallogjeri; Nancy P Judd; Gavin P Dunn; Jay F Piccirillo; James S Lewis; Elaine R Mardis; Ravindra Uppaluri
Journal:  Clin Cancer Res       Date:  2014-03-25       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.